Portfolio

Certa Therapeutics is a late stage biotechnology company based in Melbourne that is working on a treatment for diseases characterised by fibrosis and inflammation, including systemic sclerosis and kidney disease.  Certa’s novel drugs block a receptor that is a key driver of fibrosis (scarring) of the kidney which leads to organ failure and ultimately in some diseases to organ transplantation. There are currently no treatments available for kidney fibrosis and given the enormous cost of dialysis and kidney transplants to the healthcare system, finding an effective treatment for these patients remains one of the global healthcare industry’s largest unmet needs. Certa is able to use genetic analysis to identify those patients that are most likely to benefit from therapy, addressing a market worth around US$5 billion per annum in the renal indication. The technology being developed by Certa originated from the University of Melbourne, Bio21 and St Vincent’s Institute for Medical Research.

In the video below, Uniseed investee Certa Therapeutics is profiled on Channel 7 News, Melbourne.